OliPass Selected for Nucleic Acid Decoding Platform Production Service Project by Defense Science Research Institute

[Asia Economy Reporter Minji Lee] RNA therapeutic platform company Olipass announced on the 3rd that it has been selected as the contractor for the nucleic acid detoxification platform production project led by the Agency for Defense Development.

The project aims to develop nucleic acid therapeutic platform technology that can rapidly develop pandemic virus therapeutics in the event of a new virus pandemic such as COVID-19.

Olipass will design and produce antiviral therapeutic drugs using its OPNA platform technology, while the Agency for Defense Development will be responsible for evaluating the antiviral efficacy of these therapeutic drugs.

Seongcheon Kim, CSO of Olipass, said, “In the case of the United States, after the COVID-19 pandemic, through public-private partnership programs, they made every effort to secure new COVID vaccine and therapeutic development technologies, resulting in the rapid acquisition of COVID therapeutics and vaccines. By utilizing Olipass’s OPNA platform technology, which has excellent cell permeability, antiviral nucleic acid therapeutics optimized for the genetic information of pandemic viruses can be rapidly designed and developed.”

CEO Jeongshin said, “Over the past year, we have steadily developed a nucleic acid therapeutic platform that directly targets viruses. Through the development of an antiviral nucleic acid therapeutic platform capable of rapid response, we aim to contribute to securing the nation’s health sovereignty.”

This content was produced with the assistance of AI translation services.